$100,000 of DANAHER CORPORATION lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Education campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch."
You can find more data on corporate lobbying on Quiver Quantitative.
DHR Congressional Stock Trading
Members of Congress have traded $DHR stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:
- REPRESENTATIVE GREG LANDSMAN sold up to $15,000 on 03/27.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 02/26.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $50,000 on 02/25.
- SENATOR MARKWAYNE MULLIN sold up to $50,000 on 02/13.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 01/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
DHR Insider Trading Activity
DHR insiders have traded $DHR stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:
- DANIEL RASKAS (SVP - Corporate Development) has made 0 purchases and 2 sales selling 34,688 shares for an estimated $8,218,556.
- BRIAN W ELLIS (Senior Vice President - GC) sold 5,700 shares for an estimated $1,277,541
- ALAN G SPOON sold 550 shares for an estimated $113,553
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DHR Hedge Fund Activity
We have seen 842 institutional investors add shares of DHR stock to their portfolio, and 1,140 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 3,601,092 shares (-91.9%) from their portfolio in Q4 2024, for an estimated $826,630,668
- FMR LLC removed 3,097,352 shares (-13.1%) from their portfolio in Q4 2024, for an estimated $710,997,151
- D. E. SHAW & CO., INC. added 2,109,520 shares (+40977.5%) to their portfolio in Q4 2024, for an estimated $484,240,316
- WELLINGTON MANAGEMENT GROUP LLP removed 1,987,430 shares (-8.5%) from their portfolio in Q4 2024, for an estimated $456,214,556
- GAMMA INVESTING LLC added 1,863,381 shares (+24958.2%) to their portfolio in Q1 2025, for an estimated $381,993,105
- LEGAL & GENERAL GROUP PLC removed 1,636,980 shares (-28.1%) from their portfolio in Q4 2024, for an estimated $375,768,759
- TWO SIGMA ADVISERS, LP added 1,601,800 shares (+4248.8%) to their portfolio in Q4 2024, for an estimated $367,693,190
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DHR Analyst Ratings
Wall Street analysts have issued reports on $DHR in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 04/07/2025
- Guggenheim issued a "Buy" rating on 12/19/2024
- Stephens issued a "Underperform" rating on 10/23/2024
- Cowen & Co. issued a "Buy" rating on 10/23/2024
- KeyBanc issued a "Overweight" rating on 10/23/2024
- Leerink Partners issued a "Outperform" rating on 10/23/2024
- William Blair issued a "Outperform" rating on 10/22/2024
To track analyst ratings and price targets for DHR, check out Quiver Quantitative's $DHR forecast page.
DHR Price Targets
Multiple analysts have issued price targets for $DHR recently. We have seen 7 analysts offer price targets for $DHR in the last 6 months, with a median target of $275.0.
Here are some recent targets:
- An analyst from Stifel Nicolaus set a target price of $260.0 on 03/14/2025
- Matthew Sykes from Goldman Sachs set a target price of $250.0 on 01/15/2025
- Subbu Nambi from Guggenheim set a target price of $275.0 on 12/19/2024
- Doug Schenkel from Wolfe Research set a target price of $285.0 on 10/31/2024
- Paul Knight from KeyBanc set a target price of $310.0 on 10/23/2024
- Catherine Schulte from Robert W. Baird set a target price of $277.0 on 10/23/2024
- Puneet Souda from Leerink Partners set a target price of $275.0 on 10/23/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
